Publications by authors named "Lior Apter"

Claim this Profile
H
Healthcare resource utilization and associated cost in patients with metastatic non-small cell lung cancer treated in the immunotherapy era.
Lior Apter, Sarah Sharman Moser, Sivan Gazit, Gabriel Chodick, Moshe Hoshen

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer.
Sarah Sharman Moser, Shira Yaari, Lior Apter, Bernadette Poellinger, Milan Rheenen

Cancer Epidemiol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns, biomarker testing, and clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era.
Lior Apter, Sarah Sharman Moser, Ashwini Arunachalam, Sivan Gazit, Moshe Hoshen

Front Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting.
Sarah Sharman Moser, Lior Apter, Idit Livnat, Roni Ginsburg, Adva Yarden

Breast Cancer (Dove Med Press)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data.
Sarah Sharman Moser, Lior Apter, Josie Solomon, Gabriel Chodick, Miriana Wollner

Anticancer Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer.
Yasmin Leshem, Yardenna Dolev, Nava Siegelmann-Danieli, Sarah Sharman Moser, Lior Apter

Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations.
Sarah Sharman Moser, Orr Friedman Mazursky, Hadas Shalev, Lior Apter, Gabriel Chodick

Future Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer.
Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick

J Pharm Policy Pract· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of treatment initiation and mapping the cancer diagnostic pathway: A retrospective observational cohort study of patients with metastatic non-small cell lung cancer.
Sarah Sharman Moser, Shira Yaari, Damien Urban, Lior Apter, Netta Passwell

Cancer Epidemiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel.
Sarah Sharman Moser, Lior Apter, Ashwini Arunachalam, Thomas Burke, Varda Shalev

Immunotherapy· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer.
Mirela Nadler-Milbauer, Lior Apter, Ygal Haupt, Sue Haupt, Yechezkel Barenholz

J Drug Target· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis